NASDAQ:SCYX - US8112922005 - Common Stock
The current stock price of SCYX is 0.8314 USD. In the past month the price increased by 22.07%. In the past year, price decreased by -43.05%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 45.36 | 693.36B | ||
JNJ | JOHNSON & JOHNSON | 17.72 | 426.69B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 14.4 | 250.88B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18 | 247.73B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.3 | 244.98B | ||
MRK | MERCK & CO. INC. | 10.92 | 210.11B | ||
PFE | PFIZER INC | 7.3 | 140.77B | ||
SNY | SANOFI-ADR | 11.12 | 120.68B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 7.01 | 96.03B | ||
GSK | GSK PLC-SPON ADR | 8.76 | 79.92B | ||
ZTS | ZOETIS INC | 25.14 | 69.31B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.69 | 47.34B |
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 28 full-time employees. The company went IPO on 2014-05-02. The company is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. The company is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
SCYNEXIS INC
1 Evertrust Plaza, 13th Floor
Jersey City NEW JERSEY 07302 US
CEO: Marco Taglietti
Employees: 28
Phone: 12018845485
The current stock price of SCYX is 0.8314 USD. The price decreased by -2.17% in the last trading session.
The exchange symbol of SCYNEXIS INC is SCYX and it is listed on the Nasdaq exchange.
SCYX stock is listed on the Nasdaq exchange.
9 analysts have analysed SCYX and the average price target is 4.76 USD. This implies a price increase of 472.53% is expected in the next year compared to the current price of 0.8314. Check the SCYNEXIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SCYNEXIS INC (SCYX) has a market capitalization of 34.85M USD. This makes SCYX a Nano Cap stock.
SCYNEXIS INC (SCYX) currently has 28 employees.
SCYNEXIS INC (SCYX) has a support level at 0.83 and a resistance level at 0.84. Check the full technical report for a detailed analysis of SCYX support and resistance levels.
The Revenue of SCYNEXIS INC (SCYX) is expected to grow by 48.11% in the next year. Check the estimates tab for more information on the SCYX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SCYX does not pay a dividend.
SCYNEXIS INC (SCYX) will report earnings on 2025-11-04, after the market close.
SCYNEXIS INC (SCYX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
The outstanding short interest for SCYNEXIS INC (SCYX) is 1.27% of its float. Check the ownership tab for more information on the SCYX short interest.
ChartMill assigns a technical rating of 5 / 10 to SCYX. When comparing the yearly performance of all stocks, SCYX is a bad performer in the overall market: 91.26% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to SCYX. While SCYX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SCYX reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 44.44% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -32.16% | ||
ROE | -43.89% | ||
Debt/Equity | 0 |
9 analysts have analysed SCYX and the average price target is 4.76 USD. This implies a price increase of 472.53% is expected in the next year compared to the current price of 0.8314.
For the next year, analysts expect an EPS growth of 38.57% and a revenue growth 48.11% for SCYX